<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490904</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000956-29</org_study_id>
    <nct_id>NCT02490904</nct_id>
  </id_info>
  <brief_title>Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)</brief_title>
  <acronym>EPURE</acronym>
  <official_title>Double-blind Placebo-Controlled Randomised Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenon After Renal Tranplantation : Effect on Graft Function at 3 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the impact of eplerenon (administrated during 4 days in immediate pre-operative and
      post-operative period) on graft function evaluated by the measurement of glomerular
      filtration rate at 3 months - variable strongly associated with long term graft survival.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Iohexol clearance</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequence of dialysis requirement</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients presenting a delayed graft function</measure>
    <time_frame>7 days post transplant</time_frame>
    <description>The proportion of patients with a delayed graft function defined by the need of dialysis within the 7 days following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours proteinuria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of hyperkaliemia &gt; 6 mmol/l</measure>
    <time_frame>7 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lengths of initial hospital stay</measure>
    <time_frame>1 months</time_frame>
    <description>between transplantation and discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive</measure>
    <time_frame>1 year, 3 years, 10 years</time_frame>
    <description>vital status collected through the national database of organ recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatiniemia</measure>
    <time_frame>1 year, 3 years, 10 years</time_frame>
    <description>using the enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate</measure>
    <time_frame>1 year, 3 years, 10 years</time_frame>
    <description>estimation using the CKD-EPI formula (in mL/min/1.73m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an immediate renal recovery,</measure>
    <time_frame>7 days post transplant</time_frame>
    <description>The proportion of patients with an immediate renal recovery is defined by a creatininemia lower than 30 mg/L at 7 days post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iohexol clearance &lt; 30 mL/min/1,73m²</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hours microalbuminuria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a slow renal recovery</measure>
    <time_frame>7 days post transplant</time_frame>
    <description>The proportion of patients with a slow renal recovery is defined by creatininemia above 30 mg/L at 7 days post-transplant without need for dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a delayed graft function</measure>
    <time_frame>7 days post transplant</time_frame>
    <description>The proportion of patients with a delayed graft function is defined by the need for dialysis at 7 days post-transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Eplerenon group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenon administration just before and after renal tranplantation for 4 days and followed for 3 months and at 1, 3, 10 years post transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration just before and after renal tranplantation for 4 days and followed for 3 months and at 1, 3, 10 years post transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenon</intervention_name>
    <description>Double blinded Eplerenon administrated for 4 days at 25mg each 12 hours</description>
    <arm_group_label>Eplerenon group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double blinded Placebo administrated for 4 days at 25mg each 12 hours</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18

          -  Informed consent

          -  Candidate for a single or a dual kidney transplantation from a expanded criteria
             deceased donor (older than 60 years or age between 50 and 59 with 2 of the 3
             follonwing criteria: cardiovascular death, history of hypertension, creatinemia above
             130µmol/L), receving one or two kidneys, with or without conservation on perfusion
             machine

          -  Chronic hemodialysis

          -  Affiliated to social security system

        Exclusion Criteria:

          -  Multiple organs transplant (kidney and liver, kidney and heart, kidney and pancréas,
             kidney and lung, kidney and intestine)

          -  Peritoneal dialysis

          -  Preemptive transplantation

          -  Hypersensitivity or known allergy to Eplerenon or one of its excipients

          -  Patients with severe hepatic insufficiency (class Child-Pugh C)

          -  Patient receving powerful inhibitors of CYP3A4 (for example itraconazole,
             kétoconazole, ritonavir, nelfinavir, clarithromycine, télithromycine and néfazodone)

          -  Hypersensitivity or known allergy to iodized contrast agents (iohexol)

          -  Demonstrated thyrotoxicosis

          -  Hypersensitivity to lactose

          -  HLA desensitization prior to renal transplantation

          -  Pregnant woman or woman without efficient contraception

          -  Patient under protection of justice

          -  Patient under guardianship

          -  Participation in another biomedical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric JAISSER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie GIRERD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric JAISSER, Doctor</last_name>
    <phone>+33 1 44278106</phone>
    <email>frederic.jaisser@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie GIRERD, Doctor</last_name>
    <phone>+33 383157322</phone>
    <email>s.girerd@chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier DUCLOUX</last_name>
    </contact>
    <investigator>
      <last_name>Didier DUCLOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon- Hôpital Bocage Central</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane MOUSSON</last_name>
    </contact>
    <investigator>
      <last_name>Christiane MOUSSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie GIRERD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie GIRERD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP-Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe GRIMBERT</last_name>
    </contact>
    <investigator>
      <last_name>Philippe GRIMBERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Reims-Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe RIEU</last_name>
    </contact>
    <investigator>
      <last_name>Philippe RIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHC -CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno MOULIN</last_name>
    </contact>
    <investigator>
      <last_name>Bruno MOULIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 28, 2016</lastchanged_date>
  <firstreceived_date>July 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Eplerenon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
